14A5.2 Antibody Nectin-4 Epitope Recognition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers, such as breast, ovarian, and lung carcinomas, often face challenges with metastatic progression and resistance, particularly in targeting Nectin-4, a tumor-associated antigen with limited expression in normal tissues but high expression in cancer cells, necessitating the development of specific antibodies with enhanced affinity and specificity.
Innovation Solution
The development of a monoclonal antibody, 14A5.2, with a unique epitope recognition different from existing antibodies like Enfortumab Vedotin, which targets Nectin-4 with intrinsic anti-metastatic properties, allowing for the treatment of both primary and metastatic cancers, including those resistant to other therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing anti-Nectin-4 antibodies (e.g., Enfortumab Vedotin) are used, then Nectin-4 targeting is achieved, but epitope overlap limits treatment options for resistant cancers
Solution Approach 1:
The patent applies local quality by developing an antibody (14A5.2) that recognizes a specific local epitope on Nectin-4 distinct from other antibodies. This localized epitope recognition allows the antibody to bind to a specific region of the Nectin-4 protein, providing unique therapeutic activity against cancers resistant to other anti-Nectin-4 antibodies while maintaining reliable target engagement.
2Reliability
If Nectin-4 is targeted in cancers with high expression, then tumor-associated antigen targeting is achieved, but metastatic progression and therapy resistance occur
Solution Approach 1:
The patent applies preliminary action by developing an antibody with intrinsic anti-metastatic properties that can prevent metastatic progression before it occurs. The 14A5.2 antibody not only targets Nectin-4 on primary tumors but also exhibits preventive activity against metastasis, providing prolonged protection against disease progression and reducing the likelihood of therapy resistance development.
3Adaptability or versatility
If monoclonal antibody with unique epitope recognition is developed, then treatment versatility is improved, but development complexity increases
Solution Approach 1:
The patent applies copying by utilizing the framework of existing monoclonal antibody development techniques while creating a novel antibody with distinct epitope recognition. The 14A5.2 antibody was developed using established hybridoma technology and epitope mapping approaches, copying proven development methodologies to achieve a unique therapeutic agent with adapted epitope specificity that expands treatment options without requiring entirely new development paradigms.
Data Source
AI summary
The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.